142 related articles for article (PubMed ID: 23474762)
1. Mdm4 loss in mice expressing a p53 hypomorph alters tumor spectrum without improving survival.
Fang M; Simeonova I; Bardot B; Lejour V; Jaber S; Bouarich-Bourimi R; Morin A; Toledo F
Oncogene; 2014 Mar; 33(10):1336-9. PubMed ID: 23474762
[TBL] [Abstract][Full Text] [Related]
2. Mice engineered for an obligatory Mdm4 exon skipping express higher levels of the Mdm4-S isoform but exhibit increased p53 activity.
Bardot B; Bouarich-Bourimi R; Leemput J; Lejour V; Hamon A; Plancke L; Jochemsen AG; Simeonova I; Fang M; Toledo F
Oncogene; 2015 May; 34(22):2943-8. PubMed ID: 25088193
[TBL] [Abstract][Full Text] [Related]
3. A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network.
Toledo F; Krummel KA; Lee CJ; Liu CW; Rodewald LW; Tang M; Wahl GM
Cancer Cell; 2006 Apr; 9(4):273-85. PubMed ID: 16616333
[TBL] [Abstract][Full Text] [Related]
4. Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo.
Francoz S; Froment P; Bogaerts S; De Clercq S; Maetens M; Doumont G; Bellefroid E; Marine JC
Proc Natl Acad Sci U S A; 2006 Feb; 103(9):3232-7. PubMed ID: 16492744
[TBL] [Abstract][Full Text] [Related]
5. Mdm2 and Mdm4 loss regulates distinct p53 activities.
Barboza JA; Iwakuma T; Terzian T; El-Naggar AK; Lozano G
Mol Cancer Res; 2008 Jun; 6(6):947-54. PubMed ID: 18567799
[TBL] [Abstract][Full Text] [Related]
6. Mouse models of Mdm2 and Mdm4 and their clinical implications.
Xiong S
Chin J Cancer; 2013 Jul; 32(7):371-5. PubMed ID: 23327795
[TBL] [Abstract][Full Text] [Related]
7. p53 Activity Dominates That of p73 upon Mdm4 Loss in Development and Tumorigenesis.
Tashakori M; Zhang Y; Xiong S; You MJ; Lozano G
Mol Cancer Res; 2016 Jan; 14(1):56-65. PubMed ID: 26527653
[TBL] [Abstract][Full Text] [Related]
8. Spontaneous tumorigenesis in mice overexpressing the p53-negative regulator Mdm4.
Xiong S; Pant V; Suh YA; Van Pelt CS; Wang Y; Valentin-Vega YA; Post SM; Lozano G
Cancer Res; 2010 Sep; 70(18):7148-54. PubMed ID: 20736370
[TBL] [Abstract][Full Text] [Related]
9. Loss of Mdm4 results in p53-dependent dilated cardiomyopathy.
Xiong S; Van Pelt CS; Elizondo-Fraire AC; Fernandez-Garcia B; Lozano G
Circulation; 2007 Jun; 115(23):2925-30. PubMed ID: 17533180
[TBL] [Abstract][Full Text] [Related]
10. Mutation at p53 serine 389 does not rescue the embryonic lethality in mdm2 or mdm4 null mice.
Iwakuma T; Parant JM; Fasulo M; Zwart E; Jacks T; de Vries A; Lozano G
Oncogene; 2004 Oct; 23(46):7644-50. PubMed ID: 15361844
[TBL] [Abstract][Full Text] [Related]
11. Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development.
Xiong S; Van Pelt CS; Elizondo-Fraire AC; Liu G; Lozano G
Proc Natl Acad Sci U S A; 2006 Feb; 103(9):3226-31. PubMed ID: 16492743
[TBL] [Abstract][Full Text] [Related]
12. The p53 inhibitor Mdm4 cooperates with multiple genetic lesions in tumourigenesis.
Xiong S; Pant V; Zhang Y; Aryal NK; You MJ; Kusewitt D; Lozano G
J Pathol; 2017 Mar; 241(4):501-510. PubMed ID: 27925213
[TBL] [Abstract][Full Text] [Related]
13. MDM2 and MDM4: p53 regulators as targets in anticancer therapy.
Toledo F; Wahl GM
Int J Biochem Cell Biol; 2007; 39(7-8):1476-82. PubMed ID: 17499002
[TBL] [Abstract][Full Text] [Related]
14. Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53.
Parant J; Chavez-Reyes A; Little NA; Yan W; Reinke V; Jochemsen AG; Lozano G
Nat Genet; 2001 Sep; 29(1):92-5. PubMed ID: 11528400
[TBL] [Abstract][Full Text] [Related]
15. Analysis of human MDM4 variants in papillary thyroid carcinomas reveals new potential markers of cancer properties.
Prodosmo A; Giglio S; Moretti S; Mancini F; Barbi F; Avenia N; Di Conza G; Schünemann HJ; Pistola L; Ludovini V; Sacchi A; Pontecorvi A; Puxeddu E; Moretti F
J Mol Med (Berl); 2008 May; 86(5):585-96. PubMed ID: 18335186
[TBL] [Abstract][Full Text] [Related]
16. MDM4 enhances p53 stability by promoting an active conformation of the protein upon DNA damage.
Di Conza G; Mancini F; Buttarelli M; Pontecorvi A; Trimarchi F; Moretti F
Cell Cycle; 2012 Feb; 11(4):749-60. PubMed ID: 22374672
[TBL] [Abstract][Full Text] [Related]
17. Genetic and epigenetic mutations of tumor suppressive genes in sporadic pituitary adenoma.
Zhou Y; Zhang X; Klibanski A
Mol Cell Endocrinol; 2014 Apr; 386(1-2):16-33. PubMed ID: 24035864
[TBL] [Abstract][Full Text] [Related]
18. Tissue-specific differences of p53 inhibition by Mdm2 and Mdm4.
Grier JD; Xiong S; Elizondo-Fraire AC; Parant JM; Lozano G
Mol Cell Biol; 2006 Jan; 26(1):192-8. PubMed ID: 16354690
[TBL] [Abstract][Full Text] [Related]
19. G alpha 12/13 basally regulates p53 through Mdm4 expression.
Kim MS; Lee SM; Kim WD; Ki SH; Moon A; Lee CH; Kim SG
Mol Cancer Res; 2007 May; 5(5):473-84. PubMed ID: 17510313
[TBL] [Abstract][Full Text] [Related]
20. MDM4 is a rational target for treating breast cancers with mutant p53.
Miranda PJ; Buckley D; Raghu D; Pang JB; Takano EA; Vijayakumaran R; Teunisse AF; Posner A; Procter T; Herold MJ; Gamell C; Marine JC; Fox SB; Jochemsen A; Haupt S; Haupt Y
J Pathol; 2017 Apr; 241(5):661-670. PubMed ID: 28097652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
